Novel isoforms of vascular endothelial cell growth inhibitor
AssigneeGeorgetown University
InventorsLuyuan Li, Hongguang Pan
Life of this patent
Estimating the term…
Abstract
This invention discloses two new VEGI isoforms named VEGI-192a and VEGI-192b consisting of 192 amino acid residues. These isoforms show endothelial cell-specific expression and share a C-terminal 151-residues segment with the previously described VEGI-174 and VEGI-251. Methods of using these isoforms of VEGI in diagnosing, screening agonist and antagonist of the isoforms, and treating various angiogenesis-related diseases are also disclosed.
Claims56
An isolated polynucleotide comprising:
- (a) the sequence of SEQ ID NO:
- 1;
- (b) at least about 15 contiguous nucleotides of SEQ ID NO:
- 1, wherein said contiguous nucleotides are within nucleotides 1-93 of SEQ ID NO:
- 1;
- (c) at least 15 contiguous nucleotides of SEQ ID NO:
- 1, wherein said contiguous nucleotides comprise nucleotides 93 and 94 of SEQ ID NO:
- 1;
- (d) a nucleotide sequence encoding the polypeptide of SEQ ID NO:
- 4;
- (e) a nucleotide sequence encoding at least 10 contiguous amino acids of SEQ ID NO:
- 4, wherein said contiguous amino acids are within amino acids 1-26 of SEQ ID NO:
- 4;
- (f) a nucleotide sequence encoding at least 10 contiguous amino acids of SEQ ID NO:
- 4, wherein said contiguous amino acids comprise amino acids 26 and 27 of SEQ ID NO:
- 4;
- or (g) a complement of the above thereof.
An isolated polynucleotide comprising:
- (a) the sequence of SEQ ID NO:
- 2;
- (b) at least about 15 contiguous nucleotides of SEQ ID NO:
- 2, wherein said contiguous nucleotides are within nucleotides 1-386 of SEQ ID NO:
- 2;
- (c) at least 15 contiguous nucleotides of SEQ ID NO:
- 2, wherein said contiguous nucleotides comprise nucleotides 386 and 387 of SEQ ID NO:
- 2;
- (d) a nucleotide sequence encoding a polypeptide of SEQ ID NO:
- 5;
- (e) a nucleotide sequence encoding at least 10 contiguous amino acids of SEQ ID NO:
- 5, wherein said contiguous amino acids are within amino acids 1-26 of SEQ ID NO:
- 5;
- (f) a nucleotide sequence encoding at least 10 contiguous amino acids of SEQ ID NO:
- 5, wherein said contiguous amino acids comprise amino acids 26 and 27 of SEQ ID NO:
- 5;
- or (g) a complement of the above thereof.
An isolated polypeptide comprising:
- (a) the sequence of SEQ ID NO:
- 4;
- (b) at least 10 contiguous amino acids of SEQ ID NO:
- 4, wherein said contiguous amino acids are within amino acids 1-26 of SEQ ID NO:
- 4;
- or (c) at least 10 contiguous amino acids of SEQ ID NO:
- 4, wherein said contiguous comprise amino acids 26 and 27 of SEQ ID NO:
- 4.
An isolated polypeptide comprising:
- (a) the sequence of SEQ ID NO:
- 5;
- (b) at least 10 contiguous amino acids of SEQ ID NO:
- 5, wherein said contiguous amino acids are within amino acids 1-26 of SEQ ID NO:
- 5;
- or (c) at least 10 contiguous amino acids of SEQ ID NO:
- 5, wherein said contiguous comprise amino acids 26 and 27 of SEQ ID NO:
- 5.
An antibody that selectively binds to the polypeptide of SEQ ID NO:
- 4 and the polypeptide of SEQ ID NO:
- 5.
A method of inhibiting angiogenesis in a tissue or cell comprising causing an effective amount of a polypeptide encoded by the polynucleotide of SEQ ID NO:
- 3 to come into contact with, or be expressed in the proximity of, the tissue or the cell.
A therapeutic method for inhibiting angiogenesis, comprising administering to an individual a composition comprising a polynucleotide encoding the polypeptide of SEQ ID NO:
- 6 in a dosage sufficient to inhibit angiogenesis.
A therapeutic method for suppressing tumor growth comprising administering to an individual a composition comprising a polynucleotide encoding the polypeptide of SEQ ID NO:
- 6 in a pharmaceutically acceptable carrier in a dosage sufficient to suppress tumor growth.
Dependencies are inferred from the claim text.